[1] |
Matsumoto M, Miyakawa Y, Kokame K, et al. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023[J]. Int J Hematol, 2023, 118 (5): 529-546.
doi: 10.1007/s12185-023-03657-0
pmid: 37689812
|
[2] |
Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura[J]. J Thromb Haemost, 2020, 18(10): 2486-2495.
|
[3] |
Du P, Cristarella T, Goyer C, et al. A Systematic review of the epidemiology and disease burden of congenital and immune-mediated thrombotic thrombocytopenic purpura[J]. J Blood Med, 2024, 15: 363-386.
doi: 10.2147/JBM.S464365
pmid: 39161536
|
[4] |
Miesbach W, Menne J, Bommer M, et al. Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study[J]. Orphanet J Rare Dis, 2019, 14(1): 260.
doi: 10.1186/s13023-019-1240-0
pmid: 31730475
|
[5] |
Sukumar S, Lämmle B, Cataland SR. Thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, and management[J]. J Clin Med, 2021, 10(3): 536.
|
[6] |
Peyvandi F, Cataland S, Scully M, et al. Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis[J]. Blood, 2021, 5(8): 2137-2141.
|
[7] |
Mutoh T, Ohashi K, Nagai T, et al. Upfront rituximab therapy for thrombotic thrombocytopenic purpura in systemic lupus erythematosus: a case-based review[J]. Rheumatol Int, 2023, 43(2): 373-381.
|
[8] |
Liang SJ, Zheng QY, Li MS, et al. Response to belimumab in thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a case-based review[J]. Clin Rheumatol, 2022, 41(8): 2561-2569.
|
[9] |
Wright RD, Bannerman F, Beresford MW, et al. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy[J]. BMC Nephrol, 2020, 21(1):245.
doi: 10.1186/s12882-020-01888-5
pmid: 32605540
|
[10] |
Adeyemi A, Razakariasa F, Chiorean A, et al. Epidemiology, treatment patterns, clinical outcomes, and disease burden among patients with immune-mediated thrombotic thrombocytopenic purpura in the United States[J]. Res Pract Thromb Haemost, 2022, 6(6): e12802.
|
[11] |
AlGhobaishi A, Mousa AH, Alshaltoni RS, et al. Two concomitant thrombotic microangiopathies in the background of systemic lupus erythematosus: a case report[J]. Ann Med Surg (Lond), 2022, 81: 104541.
|
[12] |
Vyas A, Isaac S, Kaur D, et al. Role of the PLASMIC score in the management of thrombotic thrombocytopenic purpura[J]. Cureus, 2023, 15(3): e36188.
|
[13] |
Paydary K, Banwell E, Tong J, et al. Diagnostic accuracy of the PLASMIC score in patients with suspected thrombotic thrombocytopenic purpura: a systematic review and meta-analysis[J]. Transfusion, 2020, 60(9): 2047-2057.
|
[14] |
中华医学会血液学分会血栓与止血学组. 血栓性血小板减少性紫癜诊断与治疗中国指南(2022年版)[J]. 中华血液学杂志, 2022, 43(1): 7-12.
|
|
Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guideline on the diagnosis and management of thrombotic thrombocytopenic purpura (2022)[J]. Zhonghua Xueyexue Zazhi, 2022, 43(1): 7-12.
|
[15] |
Li J, Jiang JJ, Wang CY, et al. Clinical features and prognosis of patients with thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a review of 25 cases[J]. Ital J Pediatr, 2019, 45(1): 55.
doi: 10.1186/s13052-019-0641-y
pmid: 31036039
|
[16] |
Trisolini SM, Laganà A, Capria S. Immune thrombotic thrombocytopenic purpura: pathophysiology, diagnosis, therapy and open issues[J]. Mediterr J Hematol Infect Dis, 2024, 16(1): e2024060.
|
[17] |
Cugno M, Mancini I, Consonni D, et al. Complement activation and renal dysfunction in patients with acquired thrombotic thrombocytopenic purpura[J]. Blood, 2023, 141(18): 2278-2282.
doi: 10.1182/blood.2022018644
pmid: 36877895
|
[18] |
Selvakumar S, Liu A, Chaturvedi S. Immune thrombotic thrombocytopenic purpura: spotlight on long-term outcomes and survivorship[J]. Front Med (Lausanne), 2023, 10: 1137019.
|
[19] |
Wu H, Jay L, Lin S, et al. Interrelationship between ADAMTS13 activity, von Willebrand factor, and complement activation in remission from immune-mediated trhrombotic thrombocytopenic purpura[J]. Br J Haematol, 2020, 189(1): e18-e20.
|
[20] |
Kubo M, Matsumoto M. Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura[J]. Int J Hematol, 2023, 117(3): 331-340.
doi: 10.1007/s12185-023-03552-8
pmid: 36757521
|
[21] |
Zheng L, Zhang D, Cao W, et al. Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy[J]. Blood, 2019, 134(13): 1095-1105.
doi: 10.1182/blood.2019001040
pmid: 31409673
|
[22] |
Elhadad S, Chapin J, Copertino D, et al. MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab[J]. Clin Exp Immunol, 2021, 203(1): 96-104.
|
[23] |
Takagi Y, Kobayashi Y, Hirakata A, et al. Systemic lupus erythematosus presenting with thrombotic thrombocytopenic purpura at onset: a case report[J]. Front Pediatr, 2022, 10: 931669.
|
[24] |
Yang F, Tian J, Peng L, et al. Thrombocytopenia is an independent risk factor for the prognosis of thrombotic microangiopathy in Chinese patients with systemic lupus erythematosus[J]. Front Med (Lausanne), 2021, 8: 772607.
|
[25] |
Carvalho JF, Shoenfeld Y. Sjögren's syndrome associated with thrombotic thrombocytopenic purpura: a case-based review[J]. Rheumatol Ther, 2021, 8(1): 621-629.
doi: 10.1007/s40744-020-00265-w
pmid: 33315186
|
[26] |
Ding Y, Tan Y, Qu Z, et al. Renal microvascular lesions in lupus nephritis[J]. Ren Fail, 2020, 42(1): 19-29.
doi: 10.1080/0886022X.2019.1702057
pmid: 31858861
|
[27] |
Mingot Castellano ME, Pascual Izquierdo C, González A, et al. Recommendations for the diagnosis and treatment of patients with thrombotic thrombocytopenic purpura[J]. Med Clin (Barc), 2022, 158(12): 630.e1-630.e14.
|
[28] |
Saleem R, Rogers ZR, Neunert C, et al. Maintenance rituximab for relapsing thrombotic thrombocytopenic purpura: a case report[J]. Transfusion, 2019, 59(3): 921-926.
doi: 10.1111/trf.15093
pmid: 30548440
|
[29] |
Atrash S, Sasapu A, Pandey S, et al. Complement regulatory genetic mutations in the setting of autoimmune thrombotic thrombocytopenic purpura: a case series[J]. Mayo Clin Proc Innov Qual Outcomes, 2018, 2(1): 69-73.
doi: 10.1016/j.mayocpiqo.2017.11.004
pmid: 30225434
|